The Press Release
- Type of genomic tumor analysis demonstrated by OncoDNA in study now included in the general guidelines for the diagnosis of cancers of unknown primary origin in Spain
- Study showed OncoDEEP to predict the origins of a cancer tumor in over 80% of patients, enabling informed treatment decisions for late-stage patients
OncoDNA (“OncoDNA or “the Company”), the healthcare technology company making precision medicine a reality, today announces that the type of genomic tumor analysis demonstrated by OncoDNA’s OncoDEEP® product in a recent study is now included in the general SEAP-SEOM healthcare guidelines for the diagnosis of cancers of unknown primary origin in Spain.
In data presented at the annual congress of the Spanish Society of Medical Oncology 2018 last week, the study – entitled “Clinical impact of using a deep genomic profile in Carcinoma of Unknown Origin” – showed that OncoDEEP was able to identify the origins of a tumor in over 80% of cases, and to highlight potentially actionable mutations in over 60% of cases. The objective of the study was to design a new protocol and set of guidelines for the diagnosis and treatment of patients with advanced cancers of unknown primary origin using OncoDNA’s genomic analysis technology on the patients’ tumors.
OncoDEEP was shown to improve the diagnosis of a tumor’s primary origin and therefore detect the genetic alterations in the tumor which might inform individually-tailored treatment decisions.
The study was designed by OncoDNA and The Hospital General Universitario de Valencia and was supported by ICEX (Spain Export and Investment), and the European Regional Development Fund (ERDF). Various other reference centers in Spain, including the Hospital of La Paz and the Ramón y Cajal, both in Madrid, the Hospital Universitario Miguel Servet in Zaragoza, also participated.
Vega Iranzo, co-author of the study and spokesperson for the Oncology Department of the General University Hospital in Valencia, said:
“The results obtained have been very positive. Owing to the genomic study it was possible to predict the origin of the tumor in 80% of the patients analyzed, and potentially actionable mutations were detected in 61% of those who were potential candidates to receive a tailored treatment. Also, the additional tests of sensitivity to chemotherapies and immunotherapies allowed us to personalize the treatment in the majority of patients who began a new therapy after the study.”
Jean-Pol Detiffe, Chief Executive Officer of OncoDNA, said:
“We are pleased with the results of this study, which demonstrate that OncoDEEP’s ability to analyse the genomics of a tumor and identify mutations can inform treatment options that are specific to an individual patient’s cancer profile. Additionally, we are delighted that this study marks the inclusion of the type of genomic tumor analysis performed by our OncoDEEP product in the Spanish SEAP-SEOM healthcare guidelines for cancers of unknown primary origin. This is an important milestone for OncoDNA, offering further validation of our products and illustrating the growing recognition of our comprehensive cancer analysis tools and database among leading oncology practitioners and healthcare providers across the world.”
was the first solution developed by OncoDNA in 2013. It profiles solid tumor samples by sequencing an extensive variety of genes linked to approved targeted therapies, combined with IHC tests to detect important proteins and with other tests, such as MSI, gene fusion or promoter methylation. The NGS panel is based on an accurate analysis of oncologists’ needs in their current practice when the choice of solutions is reduced for the patients. The panel is updated every year based on advances reported in the literature, so as to provide patients with the most economical effective solutions. OncoDEEP provides information about approved or in development hormonal therapies, immunotherapies (through a personalized immunogram) and chemotherapies, as well as targeted therapies.
|OncoDNA||+32 (0) 71 18 35 00|
|Jean-Pol Detiffe, CEO|
|Pierre Flamant, CFO|
|Consilium Strategic Communications||+44 (0)20 3709 5700|
|Amber Fennell, Sukaina Virji, Nicholas Brown, Hendrik Thysfirstname.lastname@example.org|